Expression of WT1 gene in multiple myeloma patients at diagnosis: is WT1 gene expression a useful marker in multiple myeloma?

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873.
   PubMed Web of Science ®Google Scholar
• Herrinton Li, Weiss NS, Olshan AF. Epidemiology of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC. (eds) Myeloma, biology and management. Oxford: Oxford University Press, 1998; 150–186.
   Google Scholar
• Dune BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854.
   PubMed Web of Science ®Google Scholar
• Iggo N. Management of renal complications. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC. (eds) Myeloma, biology and management. Oxford: Oxford University Press, 1998; 381–401.
   Google Scholar
• Tricot G, Barlogie B, Jagannath S et al. Poor prognosis in multiplemyeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving llq and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.
   PubMed Web of Science ®Google Scholar
• Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229–2238.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Preudhomme C, Lai JL et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol 1989; 73: 61–67.
   PubMed Web of Science ®Google Scholar
• Seeker-Walker LM. Prognostic and biological importance of chromosome findings in acute lymphoblastic leukemia. Cancer Genet Cytogenet 1990; 49: 1–13.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.
   PubMed Web of Science ®Google Scholar
• Bergmann L, Miething C, Maurer U et al. High levels of Wilms' tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217–1225.
   PubMed Web of Science ®Google Scholar
• Kreuzer KA, Saborowski A, Lupberger J et al. Fluorescent 50-exonuclease assay for the absolute quantification of Wilms'tumour gene (WT1) mRNA: implications for monitoring human leukae-mias. Br J Haematol 2001; 114: 313–318.
   PubMed Web of Science ®Google Scholar
• Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409.
   PubMed Web of Science ®Google Scholar
• Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koerner HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970–977.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Yamagami T et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267–2278.
   PubMed Web of Science ®Google Scholar
• Kletzel M, Olzewski M, Huang W, Chou PM. Utility of WT1 as a reliable tool for the detection of minimal residual disease in children with leukemia. Pediatr Dev Pathol 2002; 5: 269–275.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Tamaki H, Ikegame K et al. The usefulness of monitoring WT1 gene transcripts for the prediction and manage-ment of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.
   PubMed Web of Science ®Google Scholar
• Gaiger A, Schmid D, Heinze G et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998; 12: 1886–1894.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplanta-tion. Bone Marrow Transplant 2000; 25: 91–96.
   PubMed Web of Science ®Google Scholar
• Schmid D, Heinze G, Linnerth B et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997; 11: 639–643.
   PubMed Web of Science ®Google Scholar
• Walker R, Barlogie B, Haessler J et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. JCO 2007; 25: 1121–1128.
   PubMed Web of Science ®Google Scholar
• Tribalto M, Amadori S, Cudillo L et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 2000; 85: 52–58.
   PubMed Web of Science ®Google Scholar
• Konigsberg R, Zojer N, Ackerman J et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 4: 804–812.
   Google Scholar
• Harrison CJ, Mazzullo H, Cheung KL et al. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridiza-tion results. Br J Haematol 2003; 120: 944–952.
   PubMed Web of Science ®Google Scholar
• Seong C, Delasalle K, Hayes K et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998; 101: 189–194.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M et al. Clinical and biological implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.
   PubMed Web of Science ®Google Scholar
• Hatta Y, Takeuchi T, Saitoh T et al. WT1 expression level and clinical factors in multiple myeloma. J Exp Clin Cancer Res 2005; 24: 595–599.
   PubMed Web of Science ®Google Scholar
• Lin F, Goldman JM, Cross NC. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol 1994; 86: 683–685.
   PubMed Web of Science ®Google Scholar